Increased Risk Of Major And Minor Bleeding During Antiplatelet Therapy

Increased Risk Of Major And Minor Bleeding During Antiplatelet Therapy.
Risk of bleeding for patients on antiplatelet analysis with either warfarin or a bloc of Plavix (clopidogrel) and aspirin is substantial, a supplementary study finds. Both therapies are prescribed for millions of Americans to preclude life-threatening blood clots, especially after a heart attack or stroke. But the Plavix-aspirin claque was thought to cause less bleeding than it actually does, the researchers say.

And "As with all drugs, these drugs come with risks; the most not joking is bleeding," said lead author Dr Nadine Shehab, from the US Centers for Disease Control and Prevention (CDC). While the imperil of bleeding from warfarin is well-known, the risks associated with dual psychotherapy were not well understood, she noted. "We found that the risk for hemorrhage was threefold higher for warfarin than for dual antiplatelet therapy," Shehab said. "We expected that because warfarin is prescribed much more oft-times than dual antiplatelet therapy".

However, when the researchers took the tot of prescriptions into account, the lacuna between warfarin and dual antiplatelet therapy shrank, Shehab said. "And this was worrisome," she added. For both regimens, the compute of hospital admissions because of bleeding was similar. And bleeding-related visits to crisis department visits were only 50 percent lower for those on dual antiplatelet therapy compared with warfarin, Shehab explained. "This isn't as big a imbalance as we had thought," she said.

For the study, published Monday in the Archives of Internal Medicine, Shehab's set used national databases to categorize emergency department visits for bleeding caused by either dual antiplatelet therapy or warfarin between 2006 and 2008. The investigators found 384 annual difficulty department visits for bleeding amid patients taking dual antiplatelet therapy and 2,926 annual visits for those taking warfarin.